Impact of the COVID-19 Pandemic on Essential Vitreoretinal Care with Three Epicenters in the United States

por El Hamichi, Sophia, Gold, Aaron, Heier, Jeffrey, Kiss, Szilard, Murray, Timothy G
Publicado 2020

Vascularized drusen: a cross-sectional study

por Or, Chris, Heier, Jeffrey S., Boyer, David, Brown, David, Shah, Sumit, Alibhai, Agha Yasin, Fujimoto, James G., Waheed, Nadia
Publicado 2019

The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye

por Nguyen, Quan Dong, Heier, Jeffrey S., Do, Diana V., Mirando, Adam C., Pandey, Niranjan B., Sheng, Huan, Heah, Theresa
Publicado 2020

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

por Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S.
Publicado 2022

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

por Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S.
Publicado 2022

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

por Dugel, Pravin U., Khanani, Arshad M., Berger, Brian B., Patel, Sunil, Fineman, Mitchell, Jaffe, Glenn J., Kozma-Wiebe, Petra, Heier, Jeffrey
Publicado 2021

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence

por Wykoff, Charles C., Matsumoto, Hidetaka, Barakat, Mark R., Karcher, Helene, Lozama, Anthony, Mayhook, Andrew, Oshagbemi, Olorunfemi A., Zorina, Olessia, Hassan, Tarek S., Khanani, Arshad M., Heier, Jeffrey S.
Publicado 2023

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

por Patel, Sunil S., Lally, David R., Hsu, Jason, Wykoff, Charles C., Eichenbaum, David, Heier, Jeffrey S., Jaffe, Glenn J., Westby, Keith, Desai, Dhaval, Zhu, Liansheng, Khanani, Arshad M.
Publicado 2023

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

por Patel, Sunil S., Lally, David R., Hsu, Jason, Wykoff, Charles C., Eichenbaum, David, Heier, Jeffrey S., Jaffe, Glenn J., Westby, Keith, Desai, Dhaval, Zhu, Liansheng, Khanani, Arshad M.
Publicado 2023

Expanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation

por Lally, David R., Heier, Jeffrey S., Baumal, Caroline, Witkin, Andre J., Maler, Steven, Shah, Chirag P., Reichel, Elias, Waheed, Nadia K., Bussel, Igor, Rogers, Adam, Duker, Jay S.
Publicado 2016

INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial

por Brown, David M., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Heier, Jeffrey S.
Publicado 2022

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD

por Ehlers, Justis P., Patel, Nikhil, Kaiser, Peter K., Heier, Jeffrey S., Brown, David M., Meng, Xiangyi, Reese, Jamie, Lunasco, Leina, Le, Thuy K., Hu, Ming, Srivastava, Sunil K.
Publicado 2022

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

por Heier, Jeffrey S., Ho, Allen C., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Brown, David M.
Publicado 2022

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration

por Khanani, Arshad M., Guymer, Robyn H., Basu, Karen, Boston, Heather, Heier, Jeffrey S., Korobelnik, Jean-François, Kotecha, Aachal, Lin, Hugh, Silverman, David, Swaminathan, Balakumar, Willis, Jeffrey R., Yoon, Young Hee, Quezada-Ruiz, Carlos
Publicado 2021

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration

por Ho, Allen C., Heier, Jeffrey S., Holekamp, Nancy M., Garfinkel, Richard A., Ladd, Byron, Awh, Carl C., Singh, Rishi P., Sanborn, George E., Jacobs, Jennifer H., Elman, Michael J., Loewenstein, Anat, Eichenbaum, David A.
Publicado 2021

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale

por Hattenbach, Lars-Olof, Abreu, Francis, Arrisi, Pablo, Basu, Karen, Danzig, Carl J., Guymer, Robyn, Haskova, Zdenka, Heier, Jeffrey S., Kotecha, Aachal, Liu, Ying, Loewenstein, Anat, Seres, András, Willis, Jeffrey R., Wykoff, Charles C., Paris, Liliana P.
Publicado 2023

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial

por Brown, David M., Wykoff, Charles C., Boyer, David, Heier, Jeffrey S., Clark, W. Lloyd, Emanuelli, Andres, Higgins, Patrick M., Singer, Michael, Weinreich, David M., Yancopoulos, George D., Berliner, Alyson J., Chu, Karen, Reed, Kimberly, Cheng, Yenchieh, Vitti, Robert
Publicado 2021

Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

por Liu, Kun, Wang, Hanying, He, Wei, Ye, Jian, Song, Yanping, Wang, Yusheng, Liu, Xiaoling, Wu, Zhifeng, Chen, Shaojun, Fan, Ke, Liu, Yuling, Zhang, Feng, Li, Zhiqing, Liu, Lin, Zhang, Junjun, Zhang, Xuedong, Ye, Junjie, Liang, Xiaoling, Li, Xiaoxin, Ke, Xiao, Wu, Quan, Li, Jie, Tao, Shanshan, Wang, Xinguo, Rosenfeld, Philip, Heier, Jeffrey S, Kaiser, Peter, Xu, Xun
Publicado 2022